Epirubicin hydrochloride
Synonym(s):4′-Epidoxorubicin hydrochloride;Epidoxorubicin hydrochloride
- CAS NO.:56390-09-1
- Empirical Formula: C27H30ClNO11
- Molecular Weight: 579.9802
- MDL number: MFCD00274554
- EINECS: 260-145-2
- SAFETY DATA SHEET (SDS)
- Update Date: 2024-11-19 23:02:33
What is Epirubicin hydrochloride?
Description
Epirubicin hydrochloride is an antitumor antibiotic which is epimeric with doxorubicin a t the 4’-position of the amino sugar moiety. It has shown utility in the treatment of mammary, gastric, colorectal, pulmonary and ovarian carcinomas, as well as malignant lymphoma and melanoma and soft tissue sarcoma. It is reported to be less sardiotoxic than doxorubicin.
Description
Epirubicin is a stereoisomer of the antitumor anthracycline doxorubicin that undergoes β-
Chemical properties
Orange-Red Crystalline Solid
Originator
Erbamont (Italy)
The Uses of Epirubicin hydrochloride
Used as an antineoplastic
The Uses of Epirubicin hydrochloride
Cell-permeable anthracycline anti-tumor antibiotic
What are the applications of Application
Epirubicin Hydrochloride is a cell-permeable Topo II inhibitor
brand name
Ellence(Pfizer);FARMORUBICIN.
Biological Functions
This stereoisomer of doxorubicin has the 4′-hydroxy group of the daunosamine sugar oriented in the β-position . Epirubicin will be slowly reduced to the active C13 alcohol (epirubicinol), giving it a 30- to 38-hour half life, which is similar to that of doxorubicin. Unlike doxorubicinol, however, which was equally active with doxorubicin, epirubicinol has only one-tenth the activity of its parent drug and is not believed to contribute significantly to the therapeutic action of this agent.
Biological Activity
Antibiotic antitumor agent. Inhibits the synthesis and function of DNA (IC 50 = 62.7 μ M in rat glioblastoma cell lines) and inhibits the relaxing property of topoisomerase II.
Clinical Use
Epirubicin is indicated for use in breast cancer, and the starting dose is 100 to 120 mg/m2 (compared to a starting dose of 60–75 mg/m2 for doxorubicin).
Side Effects
The side effects and precautions are as outlined previously for doxorubicin, although there is a lower risk of serious myocardial toxicity or myelotoxicity.
Drug interactions
Potentially hazardous interactions with other drugsAntipsychotics: avoid with clozapine - increased risk of agranulocytosis.Ciclosporin: increased risk of neurotoxicityCytotoxics: possible increased risk of cardiotoxicity with trastuzumab - avoid for up to 28 weeks after stopping trastuzumab.Ulcer-healing drugs: concentration increased by cimetidine. Vaccines: avoid with live vaccines
Metabolism
Cleavage of the epimerized sugar will occur before excretion, generating an aglycone that is indistinguishable from that generated by doxorubicin. Although excretion is primarily biliary, dosage reduction in severe renal impairment, as well as in hepatic dysfunction, is warranted.
storage
+4°C
References
1) Cersosimo?et al. (1986),?Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue; J. Clin. Oncol.,?4?425 2) Spadari?et al. (1986),?DNA polymerases and DNA topoisomerases as targets for the development of anticancer drugs; Anticancer Res.,?6?935 3) Minotti?et al. (2004),?Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity; Pharmacol. Rev.,?56?185 4) Mercuro?et al. (2007),?Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers; Oncologist,?12?1124
Properties of Epirubicin hydrochloride
Melting point: | 185°C dec. |
alpha | D20 +274° (c = 0.01 in methanol) |
RTECS | QI9295750 |
Flash point: | 443.8℃ |
storage temp. | Inert atmosphere,Store in freezer, under -20°C |
solubility | Soluble in DMSO to 100mM, or in ethanol to 10mM |
form | powder |
color | red to deep red |
Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or distilled water may be stored at -20° for up to 3 months. |
Safety information for Epirubicin hydrochloride
Signal word | Danger |
Pictogram(s) |
Exclamation Mark Irritant GHS07 Health Hazard GHS08 |
GHS Hazard Statements |
H302:Acute toxicity,oral H340:Germ cell mutagenicity H350:Carcinogenicity H360:Reproductive toxicity |
Precautionary Statement Codes |
P201:Obtain special instructions before use. P308+P313:IF exposed or concerned: Get medical advice/attention. |
Computed Descriptors for Epirubicin hydrochloride
InChIKey | MWWSFMDVAYGXBV-UAOJCOQHSA-N |
SMILES | C12=C(O)C3=C(C(=O)C4=C(C3=O)C=CC=C4OC)C(O)=C1[C@@]([H])(O[C@H]1O[C@@H](C)[C@H](O)[C@@H](N)C1)C[C@](O)(C(=O)CO)C2.Cl |
Abamectin manufacturer
Sakar Healthcare
BDR Pharmaceuticals International Pvt Ltd
Anand Agencies
Archerchem Healthcare Pvt., Ltd. (part of Archerchem Group)
New Products
4-Aminotetrahydropyran-4-carbonitrile Hydrochloride (R)-3-Aminobutanenitrile Hydrochloride 4-AMINO-TETRAHYDRO-PYRAN-4-CARBOXYLIC ACID HCL 4-(Dimethylamino)tetrahydro-2H-pyran-4-carbonitrile 3-((Dimethylamino)methyl)-5-methylhexan-2-one oxalate 1,4-Dioxa-8-azaspiro[4.5]decane 5-Bromo-2-nitropyridine Nimesulide BP Aceclofenac IP/BP/EP Diclofenac Sodium IP/BP/EP/USP Mefenamic Acid IP/BP/EP/USP Ornidazole IP Diclofenac Potassium SODIUM AAS SOLUTION ZINC AAS SOLUTION BUFFER SOLUTION PH 10.0(BORATE) GOOCH CRUCIBLE SINTERED AQUANIL 5 BERYLLIUM AAS SOLUTION 2-Bromo-1-(bromomethyl)-3-chloro-5-nitrobenzene 2-Bromo-3-nitroaniline N-(3-Hydroxypropyl)-N-methylacetamide 3-Bromo-6-chloropyridazine 4-ethyl-3-nitrobenzoic acidRelated products of tetrahydrofuran
You may like
-
56390-09-1 Epirubicin hydrochloride 98%View Details
56390-09-1 -
56390-09-1 98%View Details
56390-09-1 -
Epirubicin Hydrochloride (EPR.HCl) CAS 56390-09-1View Details
56390-09-1 -
Epirubicin hydrochloride CAS 56390-09-1View Details
56390-09-1 -
1823368-42-8 98%View Details
1823368-42-8 -
2-(3-(tert-butyl)phenoxy)-2-methylpropanoic acid 1307449-08-6 98%View Details
1307449-08-6 -
Ethyl 3-(furan-2-yl)-3-hydroxypropanoate 25408-95-1 98%View Details
25408-95-1 -
Lithium ClavulanateView Details
61177-44-4